Skip to main content
Terug
Watch Compare

ANAPTYSBIO, INC

Datakwaliteit: 100%
ANABV
Nasdaq Manufacturing Chemicals
€ 46,87
▲ € 3,32 (7,62%)
Marktkapitalisatie: 1,25 B
Prijs
€ 43,55
Marktkapitalisatie
1,25 B
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Revenue grew 38,82% annually over 5 years — strong growth
Generating 19,61 M in free cash flow
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 118,19%
Capital efficient — spends only 0,04% of revenue on capex

Groei

Revenue Growth (5Y)
38,82%
Boven sectorgemiddelde (1,82%)
Revenue (1Y)157,01%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
N/A
ROIC12,31%
Net Margin-5,64%
Op. Margin20,42%

Veiligheid

Debt / Equity
N/A
Current Ratio8,68
Interest CoverageN/A

Waardering

PE (TTM)
-94,65
Onder sectorgemiddelde (-1,48)
P/B RatioN/A
EV/EBITDA23,58
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -94,7 -1,5
P/B — 1,6
ROE % — -53,4
Net Margin % -5,6 -41,5
Rev Growth 5Y % 38,8 1,8
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) 157,01% Revenue Growth (3Y) 269,78%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 38,82% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 234,60 M Net Income (TTM) -13,23 M
ROE N/A ROA -3,84%
Gross Margin N/A Operating Margin 20,42%
Net Margin -5,64% Free Cash Flow (TTM) 19,61 M
ROIC 12,31% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 8,68
Interest Coverage N/A Asset Turnover 0,68
Working Capital 292,55 M Tangible Book Value -29,42 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -94,65 Forward P/E N/A
P/B Ratio N/A P/S Ratio 5,34
PEG Ratio N/A Forward PEG N/A
EV/EBITDA 23,58 Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield 1,57%
Market Cap 1,25 B Enterprise Value 1,14 B
Per Share
EPS (Diluted TTM) -0,46 Revenue / Share 8,16
FCF / Share 0,68 OCF / Share 0,68
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0,04% FCF Conversion -148,20%
SBC-Adj. FCF -16,15 M Growth Momentum 118,19

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 234,60 M 91,28 M 17,16 M 10,29 M 63,18 M
Net Income -13,23 M -145,23 M -163,62 M -128,72 M -57,80 M
EPS (Diluted) -0,46 -5,12 -6,08 -4,57 -2,11
Gross Profit — — — — —
Operating Income 47,90 M -114,95 M -164,41 M -115,15 M -56,81 M
EBITDA — — — — —
R&D Expenses — — — 88,80 M 98,50 M
SG&A Expenses — — — — —
D&A 559.000,0 606.000,0 652.000,0 675.000,0 619.000,0
Interest Expense — — — — 0,0
Income Tax 164.000,0 3.000,0 -4.000,0 24.000,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 364,40 M 483,83 M 452,39 M 610,38 M 643,07 M
Total Liabilities — — — — —
Shareholders' Equity 37,21 M 70,87 M 88,10 M 262,10 M 356,43 M
Total Debt — — — — —
Cash & Equivalents 238,20 M 123,08 M 35,97 M 71,31 M 495,73 M
Current Assets 350,25 M 431,88 M 406,84 M 447,21 M 553,88 M
Current Liabilities 38,63 M 45,43 M 37,44 M 26,05 M 16,10 M